AVROBIO up on early data from genetic disorder therapy trial

Tectonic Therapeutic

17/05/2022 17:30

** Shares of gene therapy firm  AVRO.O  rise 4.2% to $0.81
    ** Co reports positive interim data from early-stage study
of its experimental gene therapy, AVR-RD-04, in adult patients
diagnosed with infantile form of cystinosis  urn:newsml:reuters.com:*:nBw1qj0dta
    ** Cystinosis is a genetic disorder characterized by
accumulation of an amino acid called cystine in different
tissues and organs
    ** New early data show key visual motor integration, visual
perception and motor coordination measures impacted by
cystinosis stabilized or improved post gene therapy - AVRO 
    ** Six out of nine brokerages covering the stock rate it
'buy' or higher, three rate 'hold'; their median PT is $4 -
Refinitiv data 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))